Dual Agonists Explained: Why Targeting Two Hormones Changes the Maths

The shift from single-hormone to dual-hormone metabolic medication is one of the more interesting developments in recent pharmacology, and it is worth understanding mechanistically rather than just as a marketing distinction.

The incretin system

After you eat, your small intestine releases hormones called incretins. Their job is to coordinate the body's response to incoming nutrients: prompting insulin release, moderating glucagon, slowing gastric emptying, and signalling satiety to the brain.

Two incretins do most of this work. GLP-1, glucagon-like peptide-1, and GIP, glucose-dependent insulinotropic polypeptide. Both were identified decades ago, but GLP-1 became the pharmacological target first because its effects on appetite and glucose were clearer and more straightforwardly beneficial.

GIP was the more puzzling one. Its role in energy metabolism was ambiguous, and for years there was genuine scientific disagreement about whether activating or blocking GIP signalling would be the useful intervention for weight management. Some evidence pointed toward GIP promoting fat storage.

How the dual approach works

Tirzepatide is a single molecule engineered to activate both GLP-1 and GIP receptors. Its GLP-1 effects are familiar: reduced appetite, slower gastric emptying, improved insulin response, less food-seeking behaviour.

The GIP component appears to add several things. It enhances the insulin response further, particularly in the postprandial window. It appears to influence appetite regulation through pathways in the brain that are partly distinct from GLP-1 signalling. And there is evidence it improves the way adipose tissue handles lipids, potentially reducing the metabolic burden of stored fat rather than just reducing its quantity.

There is also a plausible mechanism by which GIP activation reduces the nausea associated with GLP-1 agonism, which would be clinically useful because gastrointestinal side effects are the main reason people discontinue.

The honest position is that the relative contribution of GIP remains an active research question. What is clear from head-to-head trial data is that the dual approach produces larger average weight reduction than GLP-1 monotherapy at comparable exposures.

What the trials show

The SURMOUNT programme tested tirzepatide for weight management. Average body weight reduction at the highest dose exceeded 20 percent over seventy-two weeks, with a substantial proportion of participants achieving reductions above 25 percent. For comparison, semaglutide trials at weight-management doses averaged around 15 percent.

A head-to-head trial comparing the two directly for weight loss favoured tirzepatide on magnitude of effect.

Two caveats are worth stating. These are averages with wide individual variation, and the higher average does not mean any given person will do better on one than the other. And larger effect sizes come with a side effect profile that is broadly similar in type, so the choice is not simply more effect for free.

Why "better on average" does not mean "better for you"

This is the point where trial data and clinical practice diverge usefully.

Tolerability is individual. Some people tolerate one agent noticeably better than the other, and there is no way to predict this without trying.

Comorbidities shift the calculation. Existing cardiovascular disease, kidney disease, sleep apnoea and type 2 diabetes each have their own accumulating evidence base for different agents, and outcome data beyond weight matters for treatment selection.

Supply availability is a real-world constraint. The theoretically preferable agent is not preferable if you cannot obtain a consistent supply.

Cost differs, and the difference is not trivial over a year.

And previous treatment history informs the decision. Someone who lost little on a GLP-1 monotherapy at maximum dose is a reasonable candidate for a dual agonist. Someone doing well on their current treatment has less reason to switch.

This is why anyone researching mounjaro is better served by an assessment that weighs these factors than by a comparison of headline trial numbers.

Where this is heading

The obvious next step is being pursued: triple agonists that add glucagon receptor activity to the GLP-1 and GIP combination. Early trial data has shown weight reductions approaching those achieved by bariatric surgery, which would be a genuinely significant threshold if it holds up in larger studies.

Oral formulations of these mechanisms are also progressing, which would remove the injection barrier and eventually, through competition, likely reduce cost.

The broader implication is that appetite and energy regulation are turning out to be more pharmacologically tractable than most researchers expected twenty years ago. What looked like an intractable problem is increasingly a question of which hormonal pathways to engage and in what combination. That is a meaningful shift, and it has arrived faster than the health systems paying for it have adjusted to.